

DRUG DISCOVERY TODAY**Editorial****Editor:** Steve Carney**Assistant Editor:** Karen Manser**Content Development Managers:** Sandra Korver
and Jasmin Bakker**Journal Manager:** Basil Nyaku**Publisher:** Jaap van Harten**Editorial Enquiries:***Drug Discovery Today*

Elsevier

32 Jamestown Road, London, NW1 7BY, UK

Tel: +44 (0)20 7424 4200

Fax: +44 (0)1865 853067

Email: ddt@drugdiscoverytoday.com

ADVISORY EDITORIAL BOARD**Jurgen Bajorath** *University of Bonn, Germany***Walter Blackstock** *Experimental Therapeutics
Centre, Singapore***David Brayden** *University College Dublin, Ireland***Paul Caron** *Vertex Pharmaceuticals, USA***David Cavalla** *Arachnova, UK***David Clark** *Argenta Discovery, UK***Dalia Cohen** *Rosetta Genomics, USA***Donald Daley** *Argenta Discovery, UK***Sean Ekins** *ACT LLC and Collaborations in
Chemistry, USA***Hans-Peter Fischer** *GeneData, Switzerland***Peter Ghazal** *University of Edinburgh, UK***Christopher M. Hill** *Organon, UK***Nick Hird** *Takeda Chemical Industries, Japan***Enoch Huang** *Pfizer, USA***Thomas Joos** *University of Tuebingen, Germany***Vincent H.L. Lee** *Chinese University of Hong Kong,
Hong Kong***David Lewin** *Yale University, USA***Christopher A. Lipinski** *Melior Discovery, USA***Lorenz Mayr** *Novartis, Switzerland***Nick Meanwell** *Bristol-Myers Squibb, USA***BK Muralidhara** *Pfizer Global Biologics, St. Louis,
USA***Mark Murcko** *Vertex Pharmaceuticals, USA***Fajun Nan** *Shanghai Institute of Materia Medica,
China***Pradeep Nathan** *Experimental Medicine, GSK and
University of Cambridge***Gitte Neubauer** *Cellzome, Germany***Eric Neumann** *Teranode, USA***Tim Peakman** *UK Biobank, UK***Norton Peet** *Aurigene, USA***Manuel Peitsch** *Novartis, Switzerland***Kurt Rasmussen** *Eli Lilly and Co. Ltd., USA***Janice Reichert** *Tufts Center for the Study of Drug
Development, USA***John Reidhaar-Olson** *Hoffmann-La Roche, USA***Mike Romanos** *GlaxoSmithKline, UK***Raymond C. Rowe** *Intelligensys, UK***Andreas Russ** *University of Oxford, UK***Esther Schmid** *Pfizer, UK***Jonathan Sheldon** *Inforsense, UK***Michael Snyder** *Yale University, USA***Susie Stephens** *Eli Lilly and Co. Ltd., USA***Robert Strausberg** *The J. Craig Venter Institute,
USA***Donny Strosberg** *Scripps Florida, USA***Yuichi Sugiyama** *University of Tokyo, Japan***David Szymkowski** *Xencor, USA***Nick Terrett** *Ensemble Discovery, USA***Vladimir Torchilin** *Northeastern University, Boston,
USA***Mark Whittaker** *Evotec OAI, UK***Hans Winkler** *Johnson and Johnson, Belgium***Limsoon Wong** *Laboratories for Information
Technology (LIT), Singapore***X.F. Steven Zheng** *Robert Wood Johnson Medical
School, USA*DRUG DISCOVERY
TODAY

EDITORIAL

651 New frontiers in ethnomedicine: exploring the Angolan indigenous pharmacopeia for novel antimalarial drugs*Walter Rangel Campos, Pedro Pina Catarino and Heinrich C. Hoppe*

PERSPECTIVE

FEATURE

654 New pharmacological approaches to atrial fibrillation*James T. Milnes, David J. Madge and John W. Ford***660 Orphan drug development: an economically viable strategy for biopharma R&D***Kiran N. Meekings, Cory S.M. Williams and John E. Arrowsmith***665 Relevance of systems pharmacology in drug discovery***Lourdes Cucurull-Sanchez, Karen G. Spink and Sterghios Athanasios Moschos***805 DIARY**

FORTHCOMING ARTICLES

Cell-penetrating peptides: classes, origin, and current landscape*By Francesca Milletti***Targeting mTOR as a novel therapeutic strategy for traumatic CNS injuries***By Aruni S. Arachchige Don, Chi Kwan Tsang, Tatiana M. Kazdoba, Gabriella D'Arcangelo, Wise Young and X.F. Steven Zheng***Network analysis has diverse roles in drug discovery***By Samiul Hasan, Bhushan K. Bonde, Natalie S. Buchan and Matthew D. Hall***Biologics: the next generation of analgesic drugs?***By Iain P. Chessell, Amanda Dudley and Andy Billinton*